Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label plitidepsin in myelofibrosis
2010-019790-15Phase 2Completed
- Sponsor
- PharmaMar
- Start
- Sep 2010
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plitidepsin in primary myelofibrosis (PMF) and myelofibrosis (MF), sponsored by PharmaMar. Primary endpoint: Treatment success rate. Started Sep 2010; status: completed.
02
Drugs
plitidepsin
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on 2010-019790-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019790-15.